Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Vote in favor of your Number one method for praising a birthday - 2The Way to Monetary Health: Individual budget Change
- 3The Ascent of Robots: Occupations That Man-made brainpower Might Dispense with
- 4Pilot captures jaw-dropping northern lights show from 36,000 feet (photos)
- 5Pick Your #1 Kind Of Treat
- EU states agree first step for Ukraine reparations fund
- 2 new malaria treatments announced as drug resistance grows
- More people are addicted to marijuana, but fewer of them are seeking help, experts say
- Oldest evidence of human fire-making discovered at site in England
- The most effective method to Shake Hands Expertly: A Bit by bit Guide
- Figure out How to Use the Experience of a Fender bender Legal counselor for Your Potential benefit
- EU waters down plans to end new petrol and diesel car sales by 2035
- Manual for Tracking down One of a kind Store Inns
- Why screening for the deadliest cancer in the U.S. misses most cases
